Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1953 1
1960 1
1974 1
1975 9
1976 9
1977 3
1978 9
1979 10
1980 16
1981 25
1982 16
1983 28
1984 24
1985 19
1986 20
1987 24
1988 20
1989 31
1990 26
1991 24
1992 29
1993 24
1994 28
1995 30
1996 25
1997 35
1998 36
1999 33
2000 42
2001 37
2002 51
2003 51
2004 63
2005 68
2006 76
2007 72
2008 83
2009 93
2010 88
2011 120
2012 125
2013 130
2014 117
2015 148
2016 96
2017 58
2018 107
2019 137
2020 174
2021 167
2022 144
2023 151
2024 38

Text availability

Article attribute

Article type

Publication date

Search Results

2,690 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy and safety of once-weekly semaglutide 2.0 mg versus 1.0 mg in patients with type 2 diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3B trial.
Frías JP, Auerbach P, Bajaj HS, Fukushima Y, Lingvay I, Macura S, Søndergaard AL, Tankova TI, Tentolouris N, Buse JB. Frías JP, et al. Lancet Diabetes Endocrinol. 2021 Sep;9(9):563-574. doi: 10.1016/S2213-8587(21)00174-1. Epub 2021 Jul 21. Lancet Diabetes Endocrinol. 2021. PMID: 34293304 Clinical Trial.
METHODS: We did a 40-week, randomised, active-controlled, parallel-group, double-blind, phase 3B trial (SUSTAIN FORTE) at 125 outpatient clinics in ten countries. Participants (18 years) with inadequately controlled type 2 diabetes (HbA(1c) 8.0-10.0%) with metformin and wi …
METHODS: We did a 40-week, randomised, active-controlled, parallel-group, double-blind, phase 3B trial (SUSTAIN FORTE) at 125 outpati …
Gender and Psychological Well-Being.
Matud MP, López-Curbelo M, Fortes D. Matud MP, et al. Int J Environ Res Public Health. 2019 Sep 20;16(19):3531. doi: 10.3390/ijerph16193531. Int J Environ Res Public Health. 2019. PMID: 31547223 Free PMC article.
Trimethoprim-Sulfamethoxazole.
[No authors listed] [No authors listed] 2021 Mar 17. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. 2021 Mar 17. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. PMID: 30000348 Free Books & Documents. Review.
Acetaminophen.
[No authors listed] [No authors listed] 2024 Feb 15. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. 2024 Feb 15. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. PMID: 30000253 Free Books & Documents. Review.
Cisapride.
[No authors listed] [No authors listed] 2018 Oct 31. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. 2018 Oct 31. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. PMID: 30000571 Free Books & Documents. Review.
Carfilzomib induction, consolidation, and maintenance with or without autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma: pre-planned cytogenetic subgroup analysis of the randomised, phase 2 FORTE trial.
Mina R, Musto P, Rota-Scalabrini D, Paris L, Gamberi B, Palmas A, Aquino S, de Fabritiis P, Giuliani N, De Rosa L, Gozzetti A, Cellini C, Bertamini L, Capra A, Oddolo D, Vincelli ID, Ronconi S, Pavone V, Pescosta N, Cea M, Fioritoni F, Ballanti S, Grasso M, Zamagni E, Belotti A, Boccadoro M, Gay F. Mina R, et al. Lancet Oncol. 2023 Jan;24(1):64-76. doi: 10.1016/S1470-2045(22)00693-3. Epub 2022 Dec 14. Lancet Oncol. 2023. PMID: 36528035 Clinical Trial.
In this prespecified analysis of the FORTE trial, we described the outcomes of enrolled patients according to their cytogenetic risk. ...In this preplanned analysis, we included patients enrolled in the FORTE trial with complete cytogenetic data on del(17p), t …
In this prespecified analysis of the FORTE trial, we described the outcomes of enrolled patients according to their cytogenetic risk. …
Efficacy of tirzepatide 5, 10 and 15 mg versus semaglutide 2 mg in patients with type 2 diabetes: An adjusted indirect treatment comparison.
Vadher K, Patel H, Mody R, Levine JA, Hoog M, Cheng AY, Pantalone KM, Sapin H. Vadher K, et al. Diabetes Obes Metab. 2022 Sep;24(9):1861-1868. doi: 10.1111/dom.14775. Epub 2022 Jun 13. Diabetes Obes Metab. 2022. PMID: 35589616 Free PMC article.
Aggregate data from the SURPASS-2 study that met the HbA1c inclusion criterion of the SUSTAIN FORTE study and from SUSTAIN FORTE metformin-only treated patients were used for primary analysis. RESULTS: The SURPASS-2 refined population comprised 238/245/240 and 240 p …
Aggregate data from the SURPASS-2 study that met the HbA1c inclusion criterion of the SUSTAIN FORTE study and from SUSTAIN FORTE …
Contribution des cellules tueuses naturelles chez les sujets contrôleurs d’élite du VIH.
Kant S, Dupuy FP, Kiani Z, Tremblay CL, Bernard NF. Kant S, et al. Virologie (Montrouge). 2022 Jan 1;26(1):73-89. doi: 10.1684/vir.2022.0932. Virologie (Montrouge). 2022. PMID: 35766088 French.
Cependant, la plupart des EC se distinguent des sujets non-controleurs parce qu'ils developpent de fortes reponses T CD4 et CD8 specifiques au VIH. Les cellules tueuses naturelles (NK pour Natural Killer) sont des cellules du systeme immunitaire inne qui fonctionnen …
Cependant, la plupart des EC se distinguent des sujets non-controleurs parce qu'ils developpent de fortes reponses T CD4 et CD …
Laser-induced breakdown spectroscopy.
Fortes FJ, Moros J, Lucena P, Cabalín LM, Laserna JJ. Fortes FJ, et al. Anal Chem. 2013 Jan 15;85(2):640-69. doi: 10.1021/ac303220r. Epub 2012 Dec 5. Anal Chem. 2013. PMID: 23137185 Review. No abstract available.
2,690 results